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Background
The safety and efficacy of tenofovir and emtricitabine co-
formulated tablet Truvada has been compared with
abacavir and lamivudine co-formulated tablet Kivexa in
treatment-naïve HIV patients.
Methods
We collected information about HIV patients starting
treatment with Truvada or Kivexa in combination with
efavirenz from Jan. 2006 to Dec. 2006 with follow up
through 48 weeks. Viral load (VL), CD4 count, fasting
lipid profile, and estimated GFR (Cockroft-Gault) were
measured at baseline and every 12 weeks.
Summary of results
Of 139 patients, 81 were on Truvada and 58 on Kivexa.
Most were black African (69%), mean age 38.1 (+/- 8.1)
years and 50.3% were female. Mean baseline VL was 5.4
(+/- 5.6) log10 copies/ml and CD4 count 172 (+/- 84)
cells/mm3 of blood. One patient in the Truvada arm and
one in the Kivexa discontinued for possible side-effects.
Patients on Kivexa were HLA-B* 5701 negative. At 48
weeks, on intention-to-treat analysis, VL suppression
below 400 copies/ml in Truvada and Kivexa arms were
93.5% and 96.2% (p = 0.1) and below 40 copies in 83.3%
and 85.1% (p = 0.6), respectively. Mean rise in CD4 count
was similar in both groups. Results were not predicted by
baseline VL. Increase in serum total cholesterol (TC) was
higher in Kivexa (p = 0.04), but triglycerides (TG), HDL-
cholesterol (HDL), TC/HDL and e-GFR were not different
(Table 1).
Conclusion
Truvada and Kivexa in combination with efavirenz in
treatment-naïve predominantly black African patients are
safe and effective.
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Table 1: Mean (+/- SD) serum lipids and e-GFR.
TC mmol/l TG mmol/l HDL mmol/l TC/HDL e-GFR ml/min
Truvada Baseline 4.0 (0.9) 1.3 (0.8) 1.2 (0.4) 3.6 (1.9) 104.7 (24.0)
48 weeks 4.2 (0.9) 1.3 (0.9) 1.5 (0.5) 3.3 (1.1) 108.3 (36.5)
Kivexa Baseline 4.4 (0.8) 1.5 (1.0) 1.1 (0.3) 3.8 (1.1) 104.8 (30.0)
48 weeks 5.0 (1.0) 1.5 (1.0) 1.7 (0.8) 3.3 (1.2) 117.3 (31.7)
p-values 0.04 0.7 0.7 0.3 0.1Page 2 of 2
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